Evidence map›Paper›PMID 34981062›Full record

ArticlebioRxiv : the preprint server for biology2021

Vandetanib Reduces Inflammatory Cytokines and Ameliorates COVID-19 in Infected Mice.

Ana C Puhl, Giovanni F Gomes, Samara Damasceno, Ethan J Fritch, James A Levi, Nicole J Johnson, Frank Scholle, Lakshmanane Premkumar, Brett L Hurst, Felipe LeeMontiel and 12 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 4 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 6 institutions in 2 countries.

Ana C PuhlCollaborations Pharmaceuticals, Inc., 840 Main Campus Drive, Lab 3510, Raleigh, NC 27606, USA.
Giovanni F GomesCenter for Research in Inflammatory Diseases (CRID), Ribeirao Preto Medical School, University of Sao Paulo, Avenida Bandeirantes, 3900, Ribeirao Preto, 14049-900 ; Sao Paulo, Brazil.
Samara DamascenoCenter for Research in Inflammatory Diseases (CRID), Ribeirao Preto Medical School, University of Sao Paulo, Avenida Bandeirantes, 3900, Ribeirao Preto, 14049-900 ; Sao Paulo, Brazil.
Ethan J FritchDepartment of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill NC 27599, USA.
James A LeviDepartment of Biological Sciences, North Carolina State University, Raleigh, NC, USA.
Nicole J JohnsonDepartment of Biological Sciences, North Carolina State University, Raleigh, NC, USA.
Frank ScholleDepartment of Biological Sciences, North Carolina State University, Raleigh, NC, USA.
Lakshmanane PremkumarDepartment of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill NC 27599, USA.
Brett L HurstInstitute for Antiviral Research, Utah State University, Logan, UT, USA.
Felipe LeeMontielPhenoVista Biosciences, 6195 Cornerstone Ct E. #114 San Diego CA 92121.
Flavio P VerasCenter for Research in Inflammatory Diseases (CRID), Ribeirao Preto Medical School, University of Sao Paulo, Avenida Bandeirantes, 3900, Ribeirao Preto, 14049-900 ; Sao Paulo, Brazil.
Sabrina S BatahDepartment of Pathology and Legal Medicine, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
Alexandre T FabroDepartment of Pathology and Legal Medicine, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
Nathaniel J MoormanDepartment of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill NC 27599, USA.
Boyd L YountDepartment of Epidemiology, Gillings School of Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Rebekah DickmanderDepartment of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill NC 27599, USA.
Ralph BaricDepartment of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill NC 27599, USA.
Kenneth H PearceCenter for Integrative Chemical Biology and Drug Discovery, Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina 27599, USA.
Fernando Q CunhaCenter for Research in Inflammatory Diseases (CRID), Ribeirao Preto Medical School, University of Sao Paulo, Avenida Bandeirantes, 3900, Ribeirao Preto, 14049-900 ; Sao Paulo, Brazil.
José C Alves-FilhoCenter for Research in Inflammatory Diseases (CRID), Ribeirao Preto Medical School, University of Sao Paulo, Avenida Bandeirantes, 3900, Ribeirao Preto, 14049-900 ; Sao Paulo, Brazil.
Thiago M CunhaCenter for Research in Inflammatory Diseases (CRID), Ribeirao Preto Medical School, University of Sao Paulo, Avenida Bandeirantes, 3900, Ribeirao Preto, 14049-900 ; Sao Paulo, Brazil.
Sean EkinsCollaborations Pharmaceuticals, Inc., 840 Main Campus Drive, Lab 3510, Raleigh, NC 27606, USA.
Universidade de São Paulo · BRUniversity of North Carolina at Chapel Hill · USNorth Carolina State University · USCollaborations Pharmaceuticals (United States) · USPrognosys Biosciences (United States) · USUtah State University · US

Funding

Project 4 - Influenza - UABU19AI142759 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI DENISON, MARK R · 2019 to 2023
$37.5M
Determinants of Coronavirus Fidelity in Replication and PathogenesisR01AI108197 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BARIC, RALPH S, DENISON, MARK R · 2013 to 2022
$6.5M
MegaPredict for predicting natural product uses and their drug interactionsR43AT010585 · NCCIH · COLLABORATIONS PHARMACEUTICALS, INC. · PI EKINS, SEAN · 2019 to 2020
$225k
NCCIH NIH HHS R43 AT010585NIAID NIH HHS R01 AI108197NIAID NIH HHS U19 AI142759
6 · The paper itself

Abstract

The portfolio of SARS-CoV-2 small molecule drugs is currently limited to a handful that are either approved (remdesivir), emergency approved (dexamethasone, baricitinib) or in advanced clinical trials. We have tested 45 FDA-approved kinase inhibitors

Indexed as

AntiviralentrectinibSARS-CoV-2Spike proteinvandetanib

Identifiers

PMID34981062
PMCPMC8722599
OpenAlexW4200207406

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.